Since it remained uncertain whether NSCLC with targetable drivers will benefit from immunotherapy, we further calculated the D value of different mutation subgroups, including EGFR, BRAF, ERBB2, KRAS, and MET mutations. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.